Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet
Editor’s note: I asked lung cancer expert Jack West — a thoracic oncologist at the Swedish Cancer Institute at Swedish Medical Center — to take a look at the new data from Bristol-Myers Squibb from Checkmate-227. He makes some excellent points about the way Bristol-Myers presented this data, with its broad definition of tumor mutation burden as a biomarker-defined endpoint. The detailed comments are worth studying closely. It’s clear that Bristol-Myers has a significant way to go before they can convince practitioners to change the way they treat lung cancer.
— John Carroll, Editor
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.